EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

Dates: November 12-14, 2020
Location: Rotterdam, The Netherlands
Chair: H Einsele
Co-chairs: C Chomienne, J Sierra & AA van de Loosdrecht

Organized in collaboration with: EHA & the EHA Scientific Working Group on Immune Therapies for Hematological Disorders

Registration is open. Click here

The 2nd edition of the EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders is a 3-day meeting during which participants will learn about T cell redirecting strategies (non-CAR) TCR-transfer, Innate immune cell therapy (NK, gamma/deltaTcells, DC), immune checkpoint Blockade in Hematological malignancies (preclinical/clinical work), Regulatory issues and How to combine immunotherapy?

Below you can find key information and links to important details regarding registration and accommodation. There is also a wide array of sponsorship opportunities available for pharmaceutical companies.

EHA Topics-in-Focus Immunotherapy

Topics in Focus Immunotherapy 4This meeting is part of the Topics-in-Focus program on Immunotherapy, launched by the EHA Board at EHA23. This program is aimed at raising awareness, providing education, furthering research, and building a network of experts with the ultimate goal to improve patient care.

Target audience

Hematologists, clinicians, immunologists & transfusion medicine specialists.


This meeting will cover the following topics:

  • Leukemia-reactive T cells after allogeneic HCST
  • Treatment with innate immune cells (NK, gamma/deltaTcells, DC)
  • TCR transgenic T cells
  • Checkpoint blockers
  • Other immunotherapies: Antibody, RNA and DNA based
  • Immune system and microbiome
  • Bispecific antibodies
  • Immunotherapy and laboratory testing
  • Innovative antibody formats
  • Artificial intelligence and immunotherapy

For the full program, please see this page.

Abstract & case submission

Abstract and case submission is an important part of the EHA-SWG Scientific Meeting on Immunotherapy for hematological disorders. As a participant, you have the opportunity to submit an abstract or clinical case for this meeting, and (if accepted) discuss it with the international faculty and peers.

A selection of abstracts and clinical cases will be eligible for acceptance during the meeting, the presentation format will be in the form of oral presentations or poster presentations. Presenting authors will receive a separate invitation.

Abstract and case submission is now open! More information can be found here.

Learning objectives

After attending this EHA-SWG Scientific Meeting, delegates will be able to:

  • understand T cell redirecting strategies (non-CAR) TCR-transfer,
  • understand innate immune cell therapy (NK, gamma/deltaTcells, DC),
  • understand the immune checkpoint blockade in hematological malignancies (preclinical/clinical work), and
  • understand how to combine immunotherapy.


De Doelen
Willem Burger Kwartier
Kruisplein 50, 3012 CC  Rotterdam, The Netherlands

Key dates


Online registration is open. Benefit from the reduced early registration fee by registering before July 31, 2020 (23:59 CET).

For more information and to register, please visit the registration page.


There are various opportunities to support this meeting. For more information please send an email to or check the sponsorship page.


EBAH accredited stamp DEF2

Continuing Medical Education (CME) is widely accepted to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting will be accredited by the EBAH system. Participants of this meeting are eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.